close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mainz Biomed N.V. - Ordinary Shares (NQ:MYNZ)

0.5901 -0.0299 (-4.82%)
Streaming Delayed Price Updated: 10:46 AM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mainz Biomed N.V. - Ordinary Shares

< Previous 1 2 3 4 5 Next >
News headline image
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
Hermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three of Their German Locations, Namely Ulm, Ulm-Nord, and... 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test
Collaboration to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processing 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Zöller-Kipper
Almost half of Zöller-KipperGmbH’s employees in Germany participated in the screening program so far using ColoAlert®, Mainz Biomed’s user-friendly, at-home colorectal cancer (CRC) screening test 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Presents Groundbreaking Results of ColoFuture Study
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark
Mainz Biomed team members will be available throughout the event at the Company’s booth located in Hall C, Stand C3-92 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania
Strategic Collaboration Elevates Early Cancer Detection, Bringing State-of-the-Art Diagnostic Capabilities to Romanian Population 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed’s ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
Company Anticipates Read Outs of the Clinical Data from its EU and US Feasibility Studies this September and in Q4 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
Strategic Partnership Aims to Revolutionize Cancer Screening and Enhance Healthcare Outcomes, Bringing Innovative Genetic Testing Solutions to Individuals Across Poland 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom
Collaborative Partnership Strengthens Mainz Biomed's Mission to Combat Colorectal Cancer, Saving Lives through Advanced Diagnostics 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
Israel has one of the highest screening compliance rates in the world with over one million people being screened each year 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Secures up to $50M in New Funding
Provides option to access capital to support commercial and clinical programs 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
The Company’s innovative CRC screening test will be showcased at booths 105A and 105B in cooperation with partner lab, Inicio-Instituto de Microecología 
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Expands into Romania Through Partnership with Bioclinica
From Mainz BioMed NV
Via GlobeNewswire
News headline image
Mainz Biomed Expands Commercial Footprint into Poland
Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today 
Via PressReach
Topics Death
News headline image
Being Overweight or Obese Increases Risk of Developing Colorectal Cancer
Maintaining a healthy weight is important for general health, but growing evidence reveals obesity’s role in the development of chronic illnesses and even deadly cancers. Obesity is one of the most... 
Via PressReach
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today